UBS Rates Apogee Therapeutics (APGE) hold, $135.11 Price Target

UBS analyst Michael Yee has downgraded Apogee Therapeutics to a Hold rating with a target price of $135.11, a 1.83% upside from the current price.

By EarningsIQ Research Desk · Published Jun 23, 2026, 9:01 AM EDT · Updated Jun 26, 2026, 7:02 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

UBS rated Apogee Therapeutics, Inc. ($APGE) "hold" with a $135.11 price target on June 23, 2026.

APGE Apogee Therapeutics, Inc.

$132.65 +75.05% year to date

Daily close · Jun 22, 2026

Key Points

On June 23, 2026, UBS lowered its rating on Apogee Therapeutics, Inc. (APGE) to Hold, setting a target price of $135.11.
UBS's $135.11 price target implies 1.83% upside from Apogee Therapeutics, Inc.'s ($APGE) current $132.68 share price.
The stock is currently trading at $132.68, just below its 52-week high of $135.09, indicating a tight range for investors.
The consensus among analysts shows a mean price target of $134.62, with a majority rating the stock as Hold.

Get $APGE trade alerts by text

We text you when insiders, Congress or big funds trade $APGE. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Apogee Therapeutics, Inc. alert may contain errors. Disclosures

UBS Downgrades Apogee Therapeutics

UBS analyst Michael Yee has downgraded Apogee Therapeutics, Inc. (APGE) from a previous rating to Hold. This change was made on June 23, 2026, with a target price of $135.11. The stock was trading at $132.68 at the time of the downgrade.

Analyst rating track record

UBS vs. the S&P 500

YTD return +8.01% hypothetical

All-time return +24.16% S&P 500 +25.54%

vs. S&P 500 -1.38% behind the index

Hypothetical returns from UBS's disclosed trades, not real profit or advice. How we model this.

How This Rating Compares to Other Firms

UBS's downgrade adds to a growing trend among analysts. Several other firms have also adjusted their ratings on Apogee around the same time. For instance, on June 24, 2026, Stifel downgraded the stock to Hold with a target of $135.00. TD Cowen and Guggenheim also downgraded their ratings to Hold. Mizuho rated it Neutral with a target of $135.00, indicating a general cautious sentiment in the market. This pattern suggests a shift in how analysts view Apogee's near-term prospects.

Stock Performance Near 52-Week High

Currently, Apogee's shares are trading at $132.68, which is very close to its 52-week high of $135.09. The stock has shown significant movement, reflecting investor interest. It’s worth noting that the stock's recent performance puts it just below its 50-day moving average of $134.18, indicating that it has been trading in a tight range.

12-month forecast

$APGE price target

Apogee Therapeutics, Inc. daily closes and this analyst's $135.11 target. Not advice.

Analysts Set New Price Targets

The consensus among analysts for Apogee Therapeutics points toward a mean price target of $134.62. The majority of the five analysts covering the stock have rated it as Hold, suggesting a cautious outlook. The recent downgrades from firms like Deutsche Bank and Citigroup, both on June 23, 2026, further emphasize the need for investors to be vigilant regarding the stock's performance.

What Apogee Therapeutics, Inc. Does

Apogee Therapeutics, Inc. focuses on developing biologic therapies for immunological and inflammatory diseases. With a pipeline that includes treatments for conditions like atopic dermatitis and asthma, the company is positioned in the growing biotechnology sector. As of September 2026, Apogee operates as a subsidiary of AbbVie Inc., which could influence its strategic direction and market performance.

What to Watch at Apogee Therapeutics, Inc.

Investors will be looking for further updates from analysts and any upcoming earnings reports. Apogee's next earnings date is set for November 9, 2026. As always, the 13F filings will provide insights into institutional holdings and investor sentiment in the coming months.